Utrophin up-regulation, supported by Muscular Dystrophy UK’s amazing family funds, has moved a step forward today.
Pioneered by Professor Dame Kay Davies, the drug SMTC1100 will move to Phase 2 trial. This approach could treat both Duchenne and Becker muscular dystrophies, regardless of genetic deletion or mutation.
Find out more about this encouraging news. http://bit.ly/1JmZ8Pj